23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024Globe Newswire • 20 days ago
23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting...
Share to Feed
The latest update is out from 23andMe Holding (ME). Kathy Hibbs has announced her retirement as Chief Administrative Officer and Corporate Secretar...
23andMe Holding Co. (NASDAQ:ME Get Free Report) insider Kathy L. Hibbs sold 38,548 shares of the firms stock in a transaction on Thursday, March 21st. The shares were sold at an...
23ME-01473 ('1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6 '1473 also induces Fc receptor-mediated killing of...
Built upon peer-reviewed published science, the Historical Matches feature weaves customers' ancestral connections into the story of human history and migrationSOUTH SAN FRANCISCO, Calif., March 19...
23andMe customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on polygenic risk scores (PRS) developed by...
23andMe to give an oral presentation on the genetic signature of ULBP6, the target of 23ME-01473, along with poster presentations of the biology of ULBP6 and mechanism of 23ME-01473, and new...
Wittenberg Investment Management Inc. grew its holdings in shares of 23andMe Holding Co. (NASDAQ:ME Free Report) by 88.8% in the 3rd quarter, according to the company in its most recent 13F...
Announced new non-exclusive data license with GSK, introduced 23andMe Total Health , and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473SOUTH SAN FRANCISCO...